ANTH.US Anthera Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 13, 2026
Market cap
USD 2.62K
P/E
-
P/B
0.11x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2022.

Is ANTH.US undervalued?

Graham number

The Graham number of Anthera Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Anthera Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Anthera Pharmaceuticals Inc yet.

Anthera Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Anthera Pharmaceuticals Inc

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including im…

Full company profile